| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
64,881,000 |
| Market
Cap: |
234.22(M) |
| Last
Volume: |
67,659 |
Avg
Vol: |
67,473 |
| 52
Week Range: |
$1.5 - $4.65 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Codexis discovers, develops and sells enzymes and other proteins to its clients. Co.'s business segments are: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications, as well DNA/RNA synthesis and health monitoring applications; and Novel Biotherapeutics, which discovers, improves, and/or develops biotherapeutic drug candidates, including CDX-6114 for the potential treatment of hyperphenylalaninemia. Co.'s products include biocatalysts, chemical intermediates and Codex® biocatalyst panels and kits.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,963 |
90,963 |
| Total Buy Value |
$0 |
$0 |
$156,352 |
$156,352 |
| Total People Bought |
0 |
0 |
4 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
4 |
| Total Shares Sold |
0 |
0 |
20,000 |
780,973 |
| Total Sell Value |
$0 |
$0 |
$42,168 |
$4,389,791 |
| Total People Sold |
0 |
0 |
1 |
5 |
| Total Sell Transactions |
0 |
0 |
1 |
25 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nicols John J |
President & CEO |
• • – |
2013-03-07 |
4 |
B |
$2.27 |
$61,368 |
D/D |
27,000 |
884,000 |
2.81 |
- |
|
| Nicols John J |
President & CEO |
• • – |
2013-03-06 |
4 |
B |
$2.16 |
$58,253 |
D/D |
27,000 |
857,000 |
2.81 |
- |
|
| Otoole David D |
SVP & Chief Financial Officer |
• – – |
2013-03-04 |
4 |
B |
$2.02 |
$20,222 |
D/D |
10,000 |
115,384 |
2.74 |
- |
|
| Sheehy Douglas T. |
SVP, General Counsel & Sec. |
• – – |
2013-02-10 |
4 |
D |
$2.31 |
$18,247 |
D/D |
(7,899) |
106,685 |
|
- |
|
| Tobin Matthew |
SVP, Research & Development |
• – – |
2013-02-10 |
4 |
D |
$2.31 |
$6,336 |
D/D |
(2,743) |
75,674 |
|
- |
|
| Anton David L. |
SVP, BioIndustrials |
• – – |
2013-02-10 |
4 |
D |
$2.31 |
$18,247 |
D/D |
(7,899) |
93,777 |
|
- |
|
| Seufer-Wasserthal Peter |
SVP, PharmaceuticalsOfficer |
• – – |
2013-01-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55,000 |
|
- |
|
| Tobin Matthew |
SVP, Research & Development |
• – – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
31,476 |
78,417 |
|
- |
|
| Otoole David D |
SVP & Chief Financial Officer |
• – – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
45,384 |
105,384 |
|
- |
|
| Dorgan Byron L |
Director |
– • – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,103 |
43,103 |
|
- |
|
| Karsner Alexander |
Director |
– • – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,103 |
43,103 |
|
- |
|
| Kelley Bernard J |
Director |
– • – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,103 |
68,101 |
|
- |
|
| Sheehy Douglas T. |
SVP, General Counsel & Sec. |
• – – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
45,384 |
114,584 |
|
- |
|
| Wolf Dennis P |
Director |
– • – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,103 |
43,103 |
|
- |
|
| Seufer-Wasserthal Peter |
SVP, Pharmaceuticals |
• – – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
38,064 |
93,064 |
|
- |
|
| Baruch Thomas R |
Director |
– • – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
43,103 |
45,603 |
|
- |
|
| Nicols John J |
President & CEO |
• – – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
830,000 |
|
- |
|
| Anton David L. |
SVP, BioIndustrials |
• – – |
2013-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
31,476 |
101,676 |
|
- |
|
| Otoole David D |
SVP & Chief Financial Officer |
• – – |
2012-11-12 |
4 |
B |
$2.20 |
$11,000 |
D/D |
5,000 |
60,000 |
2.74 |
- |
|
| Sheehy Douglas T. |
SVP, General Counsel & Sec. |
• – – |
2012-09-14 |
4 |
S |
$2.76 |
$10,501 |
D/D |
(3,800) |
69,200 |
|
- |
|
| Anton David L. |
SVP, BioIndustrials |
• – – |
2012-09-14 |
4 |
S |
$2.76 |
$10,480 |
D/D |
(3,800) |
70,200 |
|
- |
|
| Otoole David D |
SVP & Chief Financial Officer |
• – – |
2012-09-14 |
4 |
B |
$2.85 |
$7,125 |
D/D |
2,500 |
55,000 |
2.74 |
- |
|
| Otoole David D |
SVP & Chief Financial Officer |
• – – |
2012-09-13 |
4 |
B |
$2.70 |
$6,750 |
D/D |
2,500 |
52,500 |
2.74 |
- |
|
| Otoole David D |
SVP & Chief Financial Officer |
• – – |
2012-09-10 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Tobin Matthew |
SVP, Research & DevelopmentOff |
• – – |
2012-08-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,941 |
|
- |
|
497 Records found
|
|
Page 17 of 20 |
|
|
0.16 (4.24%) 
